Overcoming Immunological Resistance Enhances the Efficacy of a Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma

Chimeric antigen receptor (CAR) T cells have shown remarkable success in treating hematologic cancers. However, this efficacy has yet to translate to treatment in solid tumors. Pancreatic ductal adenocarcinoma (PDA) is a fatal malignancy with poor prognosis and limited treatment options. We have dev...

Full description

Bibliographic Details
Published in:Cells
Main Authors: Mahboubeh Yazdanifar, Ru Zhou, Priyanka Grover, Chandra Williams, Mukulika Bose, Laura J. Moore, Shu-ta Wu, John Maher, Didier Dreau, Pinku Mukherjee
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Subjects:
Immunotherapy
targeted therapy
pancreatic cancer
pancreatic ductal adenocarcinoma
CAR T cell
engineered T cell
MUC1
resistance
Online Access:https://www.mdpi.com/2073-4409/8/9/1070

Internet

https://www.mdpi.com/2073-4409/8/9/1070

Similar Items